Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BMY Bristol Myers Squibb	$47.07 +1.2%	$47.69	$39.71 ▼ $63.33	$94.61B	0.36	12.86 million shs	9.83 million shs
CSLLY CSL	$80.55 +0.2%	$79.03	$70.22 ▼ $109.00	$77.86B	0.79	72,887 shs	56,319 shs
GSK GSK	$38.49 +0.8%	$39.01	$31.72 ▼ $44.67	$78.19B	0.5	4.95 million shs	5.12 million shs
UCBJY UCB	$99.80 +0.5%	$92.23	$71.16 ▼ $106.60	N/A	0.51	30,124 shs	20,453 shs

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BMY Bristol Myers Squibb	-1.10%	+0.32%	-3.97%	-12.21%	+17.25%
CSLLY CSL	+0.55%	+1.52%	+1.82%	+10.36%	-20.55%
GSK GSK	-0.13%	-0.44%	-7.30%	+12.12%	-1.62%
UCBJY UCB	+3.29%	+0.61%	+7.30%	+26.45%	+27.90%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BMY Bristol Myers Squibb	4.9248 of 5 stars	3.2	3.0	4.2	4.0	3.5	3.3	1.3
CSLLY CSL	0.9497 of 5 stars	0.0	3.0	1.7	0.0	1.1	0.0	1.3
GSK GSK	2.3501 of 5 stars	1.1	4.0	2.5	0.0	2.7	0.0	2.5
UCBJY UCB	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BMY Bristol Myers Squibb	2.32	Hold	$58.00	23.22% Upside
CSLLY CSL	4.00	Strong Buy	N/A	N/A
GSK GSK	2.11	Hold	$37.38	-2.90% Downside
UCBJY UCB	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest UCBJY, BMY, GSK, and CSLLY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/3/2025	GSK GSK	Berenberg Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
4/28/2025	GSK GSK	Hsbc Global Res Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell
4/25/2025	BMY Bristol Myers Squibb	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
4/25/2025	BMY Bristol Myers Squibb	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
4/23/2025	BMY Bristol Myers Squibb	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$70.00 ➝ $68.00
4/22/2025	BMY Bristol Myers Squibb	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$55.00 ➝ $55.00
4/22/2025	BMY Bristol Myers Squibb	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$65.00
4/15/2025	GSK GSK	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$35.25
4/11/2025	BMY Bristol Myers Squibb	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$60.00 ➝ $54.00
4/8/2025	BMY Bristol Myers Squibb	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$67.00 ➝ $55.00

(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BMY Bristol Myers Squibb	$48.30B	1.98	$5.96 per share	7.90	$8.08 per share	5.83
CSLLY CSL	$14.80B	5.27	$3.99 per share	20.21	$20.07 per share	4.01
GSK GSK	$40.10B	1.97	$5.62 per share	6.85	$8.07 per share	4.77
UCBJY UCB	$6.66B	N/A	$3.97 per share	25.14	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BMY Bristol Myers Squibb	-$8.95B	$2.67	17.63	7.73	1.38	11.38%	87.62%	15.98%	7/31/2025 (Estimated)
CSLLY CSL	$2.64B	N/A	0.00	19.69	1.74	N/A	N/A	N/A	8/19/2025 (Estimated)
GSK GSK	$3.29B	$1.94	19.84	8.28	1.53	9.89%	48.82%	11.15%	7/30/2025 (Estimated)
UCBJY UCB	$1.15B	N/A	0.00	23.21	0.59	N/A	N/A	N/A	7/23/2025 (Estimated)

Latest UCBJY, BMY, GSK, and CSLLY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/31/2025	Q2 2025	BMY Bristol Myers Squibb	$1.53	N/A	N/A	N/A	$11.32 billion	N/A
7/30/2025	Q2 2025	GSK GSK	$1.12	N/A	N/A	N/A	$7.92 billion	N/A
4/30/2025	Q1 2025	GSK GSK	$1.08	$1.13	+$0.05	$1.00	$7.52 billion	$10.06 billion
4/24/2025	Q1 2025	BMY Bristol Myers Squibb	$1.50	$1.80	+$0.30	$1.21	$10.77 billion	$11.20 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BMY Bristol Myers Squibb	$2.48	5.27%	N/A	92.88%	17 Years
CSLLY CSL	$1.20	1.49%	N/A	N/A	N/A
GSK GSK	$1.69	4.39%	N/A	87.11%	N/A
UCBJY UCB	$0.48	0.48%	N/A	N/A	N/A

Latest UCBJY, BMY, GSK, and CSLLY Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/17/2025	BMY Bristol Myers Squibb	quarterly	$0.62	5.25%	7/3/2025	7/3/2025	8/1/2025
5/2/2025	GSK GSK	quarterly	$0.4216	4.1%	5/16/2025	5/16/2025	7/10/2025
4/21/2025	UCBJY UCB		$0.4838	0.62%	4/28/2025	4/29/2025	5/14/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BMY Bristol Myers Squibb	2.65	1.28	1.17
CSLLY CSL	0.45	1.86	0.85
GSK GSK	1.21	0.87	0.58
UCBJY UCB	0.30	1.36	0.99

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BMY Bristol Myers Squibb	76.41%
CSLLY CSL	0.03%
GSK GSK	15.74%
UCBJY UCB	N/A

Insider Ownership

Company	Insider Ownership
BMY Bristol Myers Squibb	0.07%
CSLLY CSL	N/A
GSK GSK	10.00%
UCBJY UCB	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BMY Bristol Myers Squibb	34,100	2.04 billion	2.03 billion	Optionable
CSLLY CSL	32,698	968.42 million	N/A	Not Optionable
GSK GSK	68,629	2.05 billion	1.84 billion	Optionable
UCBJY UCB	9,378	N/A	N/A	Not Optionable

UCBJY, BMY, GSK, and CSLLY Headlines

Recent News About These Companies

Short Interest in UCB SA (OTCMKTS:UCBJY) Rises By 165.6%

June 13, 2025 | marketbeat.com

TD Cowen maintains UCB stock Buy rating, EUR250 target

March 27, 2025 | uk.investing.com

UCB SA (UCBJY)

February 2, 2025 | finance.yahoo.com

UCB Announces U.S. Availability of 320 mg/2 mL Single-Injection Administration Option for BIMZELX® (bimekizumab-bkzx)

January 17, 2025 | finance.yahoo.com

UCB (OTC:UCBJY) Stock Quotes, Forecast and News Summary

November 22, 2024 | benzinga.com

FDA Approves UCB's Psoriasis Drug For Expanded Use In Painful Inflammatory Skin Disease

November 20, 2024 | benzinga.com

Biogen, UCB release phase 3 data on lupus candidate dapirolizumab

November 19, 2024 | msn.com

Oruka draws buy at Stifel on potential against psoriasis

October 11, 2024 | msn.com

UCB Presents New 4-year Data for BIMZELX® (bimekizumab-bkzx) in Moderate-to-Severe Plaque Psoriasis at EADV 2024

September 26, 2024 | finance.yahoo.com

Biogen/UCB Partnered Autoimmune Disease Candidate Hits Primary Goal In Late-Stage Study, Sets Stage Another Pivotal Trial

September 24, 2024 | finance.yahoo.com

UCB gets expanded FDA approval for psoriasis drug Bimzelx

September 23, 2024 | seekingalpha.com

UCB United Community Banks, Inc.

August 29, 2024 | seekingalpha.com

Barclays Sticks to Its Buy Rating for UCB SA (0NZT)

August 27, 2024 | markets.businessinsider.com

Belgium-Based Pharma Firm UCB To Offload China Neurology, Allergy Business For $680M To Asset Management Companies

August 26, 2024 | msn.com

DAY BY DAY Upgrades UCB SA - Depositary Receipt () (UCBJY)

August 12, 2024 | msn.com

Barclays Remains a Buy on UCB SA (0NZT)

July 29, 2024 | markets.businessinsider.com

UBS Keeps Their Buy Rating on UCB SA (0NZT)

July 26, 2024 | markets.businessinsider.com

UCB SA's Dividend Analysis

April 25, 2024 | finance.yahoo.com

Roche doubles down on tau for Alzheimer’s, licensing UCB drug for $120m

April 6, 2024 | pharmaphorum.comP

Drugmakers reportedly planning to raise prices on 500+ drugs in January (update)

December 29, 2023 | seekingalpha.com

Drugmakers reportedly planning to raise prices on 500+ drugs in January

December 29, 2023 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

UCBJY, BMY, GSK, and CSLLY Company Descriptions

Bristol Myers Squibb NYSE:BMY

$47.07 +0.58 (+1.25%)

Closing price 03:59 PM Eastern

Extended Trading

$46.94 -0.13 (-0.29%)

As of 07:59 PM Eastern

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

CSL OTCMKTS:CSLLY

$80.55 +0.15 (+0.19%)

As of 03:58 PM Eastern

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.

GSK NYSE:GSK

$38.49 +0.30 (+0.79%)

Closing price 03:59 PM Eastern

Extended Trading

$38.48 -0.01 (-0.03%)

As of 07:17 PM Eastern

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

UCB OTCMKTS:UCBJY

$99.80 +0.45 (+0.45%)

As of 03:56 PM Eastern

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome. In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; minzasolmin and UCB0222 for Parkinson's disease; and UCB1381 and UCB9741 for atropic dermatitis. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time